Ok, so I'll have to go back and review the slides but one of the hospitals 1/15 died (6.67%). Don't know how to calculate p values but I would have to assume that compared to 31% that is very strong. Can you imagine if Leronlimab can reduce fatality by 78%? Wow.

It also stands to reason that the M2M group would have very few, if not no deaths. Which I believe is why Nader said (paraphrasing) "It doesn't matter if we have 60 or 75 patients. Remember it's a 2:1 ratio and if there is a bad result in the placebo it counts as 2"

This tells me that the Placebo group has had some significantly negative progressions which has created a very strong p value.

I'm trying to year down my logic above (one of my evaluation strategies), but I don't see it. Please, someone tear it down.